Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Smoldering Multiple Myeloma — Management

Smoldering myeloma M-protein ≥ 3 g/dL or 10–60% plasma cells Work-up Low-risk SMM High-risk SMM (20/2/20) Stage Marrow + FLC + whole-body MRI/CT exclude active myeloma Observe Surveillance q3–6 months no therapy Early therapy Lenalidomide ± daratumumab E3A06 ↗ Trial Daratumumab AQUILA ↗